Is there a role for differentiating therapy in non-APL AML?

Best Practice and Research: Clinical Haematology

Volumn 23, Issue 4, 2010, Pages 503-508

  Koeffler, H Phillip ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

Acute myeloid leukemia; AML; CEBP; Cytokines; Differentiation; Histone deacetylase; Kinase inhibitors; Methylation; PPAR ligands; Retinoids

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; AZACITIDINE; CCAAT ENHANCER BINDING PROTEIN; COLECALCIFEROL; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; ERYTHROPOIETIN; GEFITINIB; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HEXAMETHYLENEBISACETAMIDE; HISTONE DEACETYLASE INHIBITOR; IMATINIB; INTERLEUKIN 3; INTERLEUKIN 4; INTERLEUKIN 6; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PHORBOL 13 ACETATE 12 MYRISTATE; PROTEIN TYROSINE KINASE INHIBITOR; RETINOIC ACID; RETINOID; STEM CELL FACTOR; TRANSCRIPTION FACTOR PAX5; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; VORINOSTAT;

ACUTE GRANULOCYTIC LEUKEMIA; ANGIOGENESIS; APOPTOSIS; CELL CYCLE ARREST; CELL DIFFERENTIATION; CELL STRAIN HL 60; DNA METHYLATION; IMMUNOMODULATION; LEUKEMIA CELL; NEUTROPENIA; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; REVIEW; RNA INTERFERENCE;

ANIMALS; ANTINEOPLASTIC AGENTS; CCAAT-ENHANCER-BINDING PROTEINS; CELL DIFFERENTIATION; CELL LINE, TUMOR; CRICETINAE; DISEASE MODELS, ANIMAL; GENE EXPRESSION REGULATION, LEUKEMIC; HUMANS; LEUKEMIA, MYELOID, ACUTE; LEUKEMIA, PROMYELOCYTIC, ACUTE;

EID: 78649978649     PISSN: 15216926     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.beha.2010.09.014     Document Type: Review

References (35)

1. C. Friend, W. Scher, J.G. Holland, and T. Sato Hemoglobin synthesis in murine virus-induced leukemic cells in vitro: stimulation of erythroid differentiation by dimethyl sulfoxide Proc Natl Acad Sci U S A 68 1971 378 382
2. Y. Ichikawa, D.H. Pluznik, and L. Sachs Feedback inhibition of the development of macrophage and granulocyte colonies. I. Inhibition by macrophage Proc Natl Acad Sci U S A 58 1967 1480 1486
3. M. Paran, Y. Ichikawa, and L. Sachs Feedback inhibition of the development of macrophage and granulocyte colonies. II. Inhibition by granulocytes Proc Natl Acad Sci U S A 62 1969 81 87
4. D. Metcalf Clonal extinction of myelomonocytic leukemic cells by serum from mice injected with endotoxin Int J Cancer 25 1980 225 233
5. D. Metcalf Clonal analysis of the action of GM-CSF on the proliferation and differentiation of myelomonocytic leukemic cells Int J Cancer 24 1979 616 623
6. T.R. Breitman, S.E. Selonick, and S.J. Collins Induction of differentiation of the human promyelocytic leukemia cell line (HL-60) by retinoic acid Proc Natl Acad Sci U S A 77 1980 2936 2940
7. S.J. Collins, F.W. Ruscetti, R.E. Gallagher, and R.C. Gallo Terminal differentiation of human promyelocytic leukemia cells induced by dimethyl sulfoxide and other polar compounds Proc Natl Acad Sci U S A 75 1978 2458 2462
8. H.P. Koeffler, D. Heitjan, R. Mertelsmann, J.E. Kolitz, P. Schulman, and L. Itri Randomized study of 13-cis retinoic acid v placebo in the myelodysplastic disorders Blood 71 1988 703 708
9. E.H. Estey, P.F. Thall, S. Pierce, J. Cortes, M. Beran, and H. Kantarjian Randomized phase II study of fludarabine + cytosine arabinoside + idarubicin +/- all-trans retinoic acid +/- granulocyte colony-stimulating factor in poor prognosis newly diagnosed acute myeloid leukemia and myelodysplastic syndrome Blood 93 1999 2478 2484
10. A.K. Burnett, D.W. Milligan, A.G. Prentice, A.H. Goldstone, M.F. McMullin, and R.K. Hills Modification or dose or treatment duration has no impact on outcome of AML in older patients: Preliminary results of the UK NCRI AML14 trial Blood 106 2006 162a (abstr 543)
11. A.K. Burnett, R.K. Hills, C. Green, S. Jenkinson, K. Koo, and Y. Patel The impact on outcome of the addition of all-trans retinoic acid to intensive chemotherapy in younger patients with nonacute promyelocytic acute myeloid leukemia: overall results and results in genotypic subgroups defined by mutations in NPM1, FLT3, and CEBPA Blood 115 2010 948 956
12. R.F. Schlenk, K. Dohner, M. Kneba, K. Gotze, F. Hartmann, and V.F. Del Gene mutations and response to treatment with all-trans retinoic acid in elderly patients with acute myeloid leukemia. Results from the AMLSG Trial AML HD98B Haematologica 94 2009 54 60
13. P.J. Hughes, E. Marcinkowska, E. Gocek, G.P. Studzinski, and G. Brown Vitamin D3-driven signals for myeloid cell differentiation-implications for differentiation therapy Leuk Res 34 2010 553 565
14. A. Petrich, B. Kahl, H. Bailey, K. Kim, N. Turman, and M. Juckett Phase II study of doxercalciferol for the treatment of myelodysplastic syndrome Leuk Lymphoma 49 2008 57 61
15. G.D. Demetri, C.D. Fletcher, E. Mueller, P. Sarraf, R. Naujoks, and N. Campbell Induction of solid tumor differentiation by the peroxisome proliferator-activated receptor-gamma ligand troglitazone in patients with liposarcoma Proc Natl Acad Sci U S A 96 1999 3951 3956
16. P. Tontonoz, S. Singer, B.M. Forman, P. Sarraf, J.A. Fletcher, and C.D. Fletcher Terminal differentiation of human liposarcoma cells induced by ligands for peroxisome proliferator-activated receptor gamma and the retinoid X receptor Proc Natl Acad Sci U S A 94 1997 237 241
17. S.B. Shappell, R.A. Gupta, S. Manning, R. Whitehead, W.E. Boeglin, and C. Schneider 15S-Hydroxyeicosatetraenoic acid activates peroxisome proliferator-activated receptor gamma and inhibits proliferation in PC3 prostate carcinoma cells Cancer Res 61 2001 497 503
18. E. Mueller, M. Smith, P. Sarraf, T. Kroll, A. Aiyer, and D.S. Kaufman Effects of ligand activation of peroxisome proliferator-activated receptor gamma in human prostate cancer Proc Natl Acad Sci U S A 97 2000 10990 10995
19. M. Konopleva, E. Elstner, T.J. McQueen, T. Tsao, A. Sudarikov, and W. Hu Peroxisome proliferator-activated receptor gamma and retinoid X receptor ligands are potent inducers of differentiation and apoptosis in leukemias Mol Cancer Ther 3 2004 1249 1262
20. L.M. Souza, T.C. Boone, J. Gabrilove, P.H. Lai, K.M. Zsebo, and D.C. Murdock Recombinant human granulocyte colony-stimulating factor: effects on normal and leukemic myeloid cells Science 232 1986 61 65
21. J. Skokowa, M. Germeshausen, C. Zeidler, and K. Welte Severe congenital neutropenia: inheritance and pathophysiology Curr Opin Hematol 14 2007 22 28
22. G. Rovera, D. Santoli, and C. Damsky Human promyelocytic leukemia cells in culture differentiate into macrophage-like cells when treated with a phorbol diester Proc Natl Acad Sci U S A 76 1979 2779 2783
23. K. Stegmaier, S.M. Corsello, K.N. Ross, J.S. Wong, D.J. DeAngelo, and T.R. Golub Gefitinib induces myeloid differentiation of acute myeloid leukemia Blood 106 2005 2841 2848
24. S. Boehrer, L. Ades, T. Braun, L. Galluzzi, J. Grosjean, and C. Fabre Erlotinib exhibits antineoplastic off-target effects in AML and MDS: a preclinical study Blood 111 2008 2170 2180
25. T. Wossning, S. Herzog, F. Kohler, S. Meixlsperger, Y. Kulathu, and G. Mittler Deregulated Syk inhibits differentiation and induces growth factor-independent proliferation of pre-B cells J Exp Med 203 2006 2829 2840
26. F. Klein, N. Feldhahn, L. Harder, H. Wang, M. Wartenberg, and W.K. Hofmann The BCR-ABL1 kinase bypasses selection for the expression of a pre-B cell receptor in pre-B acute lymphoblastic leukemia cells J Exp Med 199 2004 673 685
27. R.C. Reuben, R.L. Wife, R. Breslow, R.A. Rifkind, and P.A. Marks A new group of potent inducers of differentiation in murine erythroleukemia cells Proc Natl Acad Sci U S A 73 1976 862 866
28. V.M. Richon, Y. Webb, R. Merger, T. Sheppard, B. Jursic, and L. Ngo Second generation hybrid polar compounds are potent inducers of transformed cell differentiation Proc Natl Acad Sci U S A 93 1996 5705 5708
29. C.B. Miller, C.G. Mullighan, and J.R. Downing Mutations in the B-cell transcription factor PAX5 found in B-progenitor acute lymphoblastic leukemia impair normal PAX5 activity Blood 108 2006 185a (abstr 613)
30. D. Nowak, N. Kawamata, B. Niebuhr, V. Nowak, M. Mossner, and R.R. Nahar The Pax5 fusion product Pax5-C20orf112 causes downregulation of pre-B cell receptor genes and induces differential proliferation patterns in B-lymphoblastic cell lines Blood 114 2009 526 (abstr 1284)
31. K. Wagner, P. Zhang, F. Rosenbauer, B. Drescher, S. Kobayashi, and H.S. Radomska Absence of the transcription factor CCAAT enhancer binding protein alpha results in loss of myeloid identity in bcr/abl-induced malignancy Proc Natl Acad Sci U S A 103 2006 6338 6343
32. E. Duprez, K. Wagner, H. Koch, and D.G. Tenen C/EBPbeta: a major PML-RARA-responsive gene in retinoic acid-induced differentiation of APL cells EMBO J 22 2003 5806 5816
33. Y.J. Lee, L.C. Jones, N.A. Timchenko, D. Perrotti, D.G. Tenen, and S.C. Kogan CCAAT/enhancer binding proteins alpha and epsilon cooperate with all-trans retinoic acid in therapy but differ in their antileukemic activities Blood 108 2006 2416 2419
34. J. O'Malley, K. Woltjen, and K. Kaji New strategies to generate induced pluripotent stem cells Curr Opin Biotechnol 20 2009 516 521
35. H.P. Koeffler Induction of differentiation of human acute myelogenous leukemia cells: therapeutic implications Blood 62 1983 709 721